Case Reports in Oncological Medicine

Case Reports in Oncological Medicine / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 8201917 | 3 pages | https://doi.org/10.1155/2018/8201917

Cardiac Tamponade as the Initial Presentation of Acute Myeloid Leukemia: A Case Report with Review of the Literature

Academic Editor: Jeanine M. Buchanich
Received18 Jan 2018
Accepted22 Feb 2018
Published26 Mar 2018

Abstract

Acute myeloid leukemia (AML) is a complex disease with a variety of presentations. A large pericardial effusion is rare, occurring in less than 0.5% of all patients with AML prior to treatment. A 34-year-old male presented with dyspnea, malaise, and weight loss. On physical exam, he was noted to be hypoxic, tachypneic, tachycardic, and hypotensive. He had cervical lymphadenopathy and jugular venous distention. His WBC count was 110 bil/L with 33% blasts. Bone marrow biopsy confirmed AML with 60% blasts. Leukemic cells were also seen in the cerebrospinal fluid on lumbar puncture. An echocardiogram revealed a large pericardial effusion causing tamponade. He underwent emergent pericardiocentesis, and malignant cells were present in the pericardial fluid. Induction therapy with standard dose cytarabine and daunorubicin was initiated, and bone marrow biopsy 14 days later showed no residual AML. This case demonstrates the importance of a thorough evaluation of each organ system when caring for a patient with AML.

1. Introduction

Acute myeloid leukemia (AML) is a complex disease with a variety of presentations. Majority of patients present with symptoms related to bone marrow failure such as fatigue, bruising or bleeding, fever, and infection [1]. Pericardial effusion can occur in patients with AML, but a large pericardial effusion is rare, occurring in less than 0.5% of all patients with AML prior to treatment [2]. Cardiac tamponade in AML is exceedingly rare, with only few cases reported in the literature. In this report, we describe a case of AML with cardiac tamponade as the initial presentation.

2. Case Description

A 34-year-old male without any significant past medical history presented to the hospital with shortness of breath, malaise, and unintentional weight loss. On physical exam, he was noted to be hypoxic, tachypneic, tachycardic, and hypotensive. He had palpable cervical lymphadenopathy and jugular venous distention. Complete blood count showed hyperleukocytosis (white blood cell count (WBC) of 110 bil/L with 33% blasts) and severe anemia (hemoglobin of 4.0 g/dL). Peripheral blood smear demonstrated increased blasts with promonocytes consistent with AML (Figure 1). His EKG showed sinus tachycardia and low-voltage QRS.

Given his dyspnea, hemodynamic abnormalities, and jugular venous distension, an emergent echocardiogram was obtained which revealed a large pericardial effusion with right atrial and ventricular collapse consistent with cardiac tamponade (Figure 2). Pericardiocentesis was performed, and leukemic blasts were seen on fluid analysis. Despite a lack of neurological symptoms, a lumbar puncture was performed as he was deemed high risk for central nervous system (CNS) involvement due concern for acute myelomonocytic leukemia (AMML). Cerebrospinal fluid analysis revealed 99 WBCs with 35% blasts consistent with leukemic involvement. Bone marrow biopsy was consistent with AMML (Figure 3). Cytogenetics revealed no abnormalities. On genotyping, NPM1, FLT-3, CEBP-A, and C-KIT were negative.

His dyspnea, tachypnea, tachycardia, hypotension, and hypoxia resolved following pericardiocentesis. Given his hemodynamic instability, treatment with standard dose 7 + 3 cytarabine with daunorubicin was preferred over high-dose cytarabine with daunorubicin.

The pericardial effusion did not reaccumulate, and he did not require a repeat pericardiocentesis. Bone marrow biopsy performed on day 14 of treatment did not show any residual AML. His blood counts recovered to normal, and he was started on intrathecal methotrexate. He is currently undergoing bone marrow transplant evaluation.

3. Discussion

Pericardial tamponade as an initial presentation of AML is a rare entity. A thorough literature review identified only three prior reported such cases in adults [35]. The clinical presentations of these cases have been summarized in Table 1. Two of the three patients described in the literature (Table 1) died within 24 hours. In a prior study evaluating 1600 patients with different types of leukemia, it is described that pericardial effusion was detected in 21% of patients with AML [2]. In more than two-thirds of these patients, the effusions occurred after receiving some form of therapy, whereas the remainders of effusions were present before therapy, and none was the initial presentation.


Patient demographicsSigns of tamponadeChemotherapeutic regimenOutcome

32-year-old male [3]PresentNonePatient died within 24 hours of admission
28-year-old male [4]PresentIntrapericardial mitoxantroneComplete remission
73-year-old female [5]NoneNonePatient died prior to pericardiocentesis

Approximately half of patients with symptomatic pericardial disease and an underlying cancer may have nonmalignant pericardial disease including radiation pericarditis, drug-induced pericarditis, infection, hypothyroidism, autoimmune disorders, and idiopathic pericarditis [6]. In our case, we were able to establish AML as the clear culprit behind the pericardial effusion by demonstrating blast cells in the pericardial fluid. It is important to consider these other causes of pericardial effusion when such a clear relationship between the malignancy and the pericardial effusion cannot be established.

Although poorly understood, the pathophysiology behind the relationship between leukemia and acute pericardial disease is thought to be related to multiple factors including hemorrhage caused by concurrent thrombocytopenia, infections due to underlying immune deficiency, and direct malignant cell infiltration [7, 8]. While the prognostic and therapeutic implications of malignant effusions in AML are not entirely known, it appears that an effusion large enough to cause tamponade increases mortality.

Our case also highlights the importance of evaluating for CNS involvement in patients with AML. Central nervous system (CNS) involvement occurs in around 0.6% of adult patients with AML at initial presentation [9]. These patients may not have any CNS symptoms [10], as was seen in our case as well. Not all patients with AML require a lumbar puncture, but the decision to perform a lumbar puncture should not only rest on CNS symptoms but also on the presence of other risk factors for CNS involvement such as prominent monocytic component, acute promyelocytic leukemia, and certain molecular and cytogenetic findings among many others [912].

4. Conclusions

In conclusion, our case demonstrates the importance of a thorough evaluation of each organ system when caring for a patient with AML. Pericardial effusion causing cardiac tamponade can be one of the initial presentations of AML and requires early recognition and prompt intervention to improve outcome.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors want to thank and acknowledge Dr. Sandra Gjorgova-Gjeorgjievski and Dr. Marc Smith for their help with preparing and interpreting the pathology slides.

References

  1. E. J. Jabbour, E. Estey, and H. M. Kantarjian, “Adult acute myeloid leukemia,” Mayo Clinic Proceedings, vol. 81, no. 2, pp. 247–260, 2006. View at: Publisher Site | Google Scholar
  2. K. Sampat, A. Rossi, V. Garcia-Gutierrez et al., “Characteristics of pericardial effusions in patients with leukemia,” Cancer, vol. 116, no. 10, p. 2366, 2010. View at: Publisher Site | Google Scholar
  3. J. Leptidis, S. Aloizos, P. Chlorokostas, and S. Gourgiotis, “Fatal cardiac tamponade as the first manifestation of acute myeloid leukemia,” American Journal of Emergency Medicine, vol. 32, no. 10, pp. 1294e1–1294e2, 2014. View at: Publisher Site | Google Scholar
  4. M. Kawasaki, Y. Yamano, Y. Kikuchi, T. Sata, M. Harada, and Y. Niho, “Cardiac tamponade as an initial manifestation of acute myeloblastic leukemia,” Rinsho Ketsueki, vol. 31, no. 2, pp. 224–228, 1990. View at: Google Scholar
  5. M. Björkholm, A. Ost, and P. Biberfeld, “Myocardial rupture with cardiac tamponade as a lethal early manifestation of acute myeloblastic leukemia,” Cancer, vol. 50, no. 9, pp. 1867–1869, 1982. View at: Publisher Site | Google Scholar
  6. J. Kralstein and W. Frishman, “Malignant pericardial diseases: diagnosis and treatment,” American Heart Journal, vol. 113, no. 3, pp. 785–790, 1987. View at: Publisher Site | Google Scholar
  7. H. R. Bierman, E. K. Perkins, and P. Ortega, “Pericarditis in patients with leukemia,” American Heart Journal, vol. 43, no. 3, pp. 413–422, 1952. View at: Publisher Site | Google Scholar
  8. E. A. Dragoescu and L. Liu, “Pericardial fluid cytology: an analysis of 128 specimens over a 6-year period,” Cancer Cytopathology, vol. 121, no. 5, pp. 242–251, 2013. View at: Publisher Site | Google Scholar
  9. N. Alakel, F. Stölzel, B. Mohr et al., “Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia,” Cancer Management and Research, vol. 9, pp. 97–102, 2017. View at: Publisher Site | Google Scholar
  10. S. Ranta, M. Palomäki, M. Levinsen et al., “Presenting features and imaging in childhood acute myeloid leukemia with central nervous system involvement,” Pediatric Blood and Cancer, vol. 64, no. 12, p. e26459, 2017. View at: Publisher Site | Google Scholar
  11. R. Holmes, M. J. Keating, A. Cork et al., “A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22),” Blood, vol. 65, no. 5, pp. 1071–1078, 1985. View at: Google Scholar
  12. F. Shihadeh, V. Reed, S. Faderl et al., “Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease,” Cancer, vol. 118, no. 1, pp. 112–117, 2012. View at: Publisher Site | Google Scholar

Copyright © 2018 Dillon Karmo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1302 Views | 275 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.